Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
Cardiometabolic Medicine Center, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
Cardiovasc Diabetol. 2023 Jun 22;22(1):146. doi: 10.1186/s12933-023-01875-8.
The occurrence and development of coronary heart disease (CHD) are closely linked to fluctuations in blood glucose levels. While the efficacy of intensified treatment guided by HbA1c levels remains uncertain for individuals with diabetes and CHD, this review summarizes the findings and conclusions regarding HbA1c in the context of CHD. Our review showed a curvilinear correlation between regulated level of HbA1c and therapeutic effectiveness of intensified glycemic control among patients with type 2 diabetes and coronary heart disease. It is necessary to optimize the dynamic monitoring indicators of HbA1c, combine genetic profiles, haptoglobin phenotypes for example and select more suitable hypoglycemic drugs to establish more appropriate glucose-controlling guideline for patients with CHD at different stage of diabetes.
冠心病（CHD）的发生和发展与血糖水平的波动密切相关。虽然糖尿病和 CHD 患者的 HbA1c 指导强化治疗的疗效尚不确定，但本综述总结了 HbA1c 与 CHD 相关的研究结果和结论。我们的综述表明，在 2 型糖尿病和冠心病患者中，HbA1c 的控制水平与强化血糖控制的治疗效果之间存在曲线相关关系。有必要优化 HbA1c 的动态监测指标，结合遗传图谱、结合珠蛋白表型等，并选择更合适的降糖药物，为不同糖尿病阶段的 CHD 患者制定更合适的血糖控制指南。
